AC Immune SA
NASDAQ:ACIU
AC Immune SA
NASDAQ:ACIU
Price:
2.35 USD
2.62%
Market Closed
Updated:
Apr 28, 2024
AC Immune SA
Operating Income
|
AC Immune SA
Operating Income Peer Comparison
Comparables:
ADCT
CRSP
BSLN
IDIA
KURN
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
AC Immune SA
NASDAQ:ACIU
|
Operating Income
-CHf53.6m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Operating Income
-$166m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Operating Income
-$222.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Operating Income
CHf19.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Operating Income
-CHf803m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-152%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Operating Income
-CHf8.7m
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
See Also
What is AC Immune SA's Operating Income?
Operating Income
-53.6m
CHF
-53.6m
CHF
Based on the financial report for Dec 31, 2023, AC Immune SA's Operating Income amounts to -53.6m CHF.
What is AC Immune SA's Operating Income growth rate?
Operating Income CAGR 5Y
-2%
-2%
Over the last year, the Operating Income growth was 24%. The average annual Operating Income growth rates for AC Immune SA have been 4% over the past three years , -2% over the past five years .
You don't have any saved screeners yet
